Clinical Trial: Stiripentol in Dravet Syndrome

Study Status: No longer available
Recruit Status: No longer available
Study Type: Expanded Access

Official Title: Compassionate Use of Stiripentol in Intractable Epilepsy Due to Dravet Syndrome

Brief Summary: The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.

Detailed Summary:
Sponsor: Mayo Clinic

Current Primary Outcome:

Original Primary Outcome: Mean monthly seizure frequency [ Time Frame: 1 yr ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Mayo Clinic

Dates:
Date Received: February 9, 2012
Date Started: February 2012
Date Completion: February 2013
Last Updated: February 26, 2013
Last Verified: February 2013